Wave Life Sciences shares plunged 49.59% to $6.20 on Thursday after higher-dose WVE-007 obesity data unexpectedly underperformed the lower dose; trading volume surged to ~49.9M shares. The disappointing dose-response data is a significant negative for the WVE-007 program and materially reduces the company's clinical-stage valuation, triggering heavy investor sell-off.
Wave Life Sciences shares plunged 49.59% to $6.20 on Thursday after higher-dose WVE-007 obesity data unexpectedly underperformed the lower dose; trading volume surged to ~49.9M shares. The disappointing dose-response data is a significant negative for the WVE-007 program and materially reduces the company's clinical-stage valuation, triggering heavy investor sell-off.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly negative
Sentiment Score
-0.75
Ticker Sentiment
